Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

What Is the Best Timing for Bispecific Antibodies and CAR-T Therapy …

SOHO Brazil 2024

A. Zelenetz

Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas

University of Colorado Division of Hematology

M. Kamdar

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Moffitt Cancer Center

A. Lazaryan

Polatuzumab Vedotin in 1L DLBCL: Perspectives on the POLARIX Trial

Juan Pablo Alderuccio

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

POLARIX Trial Recap: Using Polatuzumab Vedotin for Previously Untrea…

Thomas Melchardt

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

Georg Lenz

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

New Updates in Frontline DLBCL

Scripps Health

L. Nastoupil

Current Standards of Care for Aggressive Lymphomas

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

U. Vitolo

Upfront Management of DLBCL

SOHO 2023 Eleventh Annual Meeting

C. Flowers

Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

Wojciech Jurczak